Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Hysterektomi ved transvaginal naturlig åpning Transluminal endoskopisk kirurgi versus eller laparoskopisk hysterektomi (vNOTESHC)

29. september 2026 oppdatert av: Centre Hospitalier Universitaire de Saint Etienne

vNOTESHC: Hysterektomi ved transvaginal naturlig åpning Transluminal endoskopisk kirurgi versus eller laparoskopisk hysterektomi: en randomisert kontrollert prøvelse

In France, there are approximately 62,000 hysterectomies per year, 70% of which are benign. It is the most frequent surgical procedure in gynecology.

Hysterectomies are performed via 3 routes: laparotomy, laparoscopy or vaginal route.

This choice of approach is particularly important in the case of large uteri (50% of uteri > 280g), which increase the risks of laparoconversion and bladder injury (NP3).

The vaginal route reduces the operating time and postoperative pain. Laparoscopy allows a better anatomical view and easier access to the neighbouring organs, which makes it the preferred approach, especially for young surgeons and when the uterus is large. However, the laparoscopic route is associated with an increase in the rate of conversion to laparotomy according to the volume of the uterus, as well as the rate of general per and postoperative complications compared with vaginal hysterectomy for uteri > 280 g. In a meta-analysis comparing laparoscopy and vaginal hysterectomy, the total prevalence of perioperative complications according to the classification of Clavien and Dindo was 27%. For large uteruses, complications by the vaginal route amounted to 15% and those by the laparoscopic route to 37.5%.

The data are not sufficient to give preference to one or other of the approaches, but for benign pathologies, for large uteri (>280 g), the minimally invasive laparoscopic or vaginal approaches are recommended by the CNGOF (grade C).

A new Medical Device (MD), the vNOTES (Vaginal Natural Orifice Transluminal Endoscopy System) offers the advantage of two approaches for pelvic surgery by allowing minimally invasive surgery to be performed by endoscopy through the vagina, offering perfect vision for the assistants and the operator and without scarring. Two randomized trials have shown that vNOTES allows, compared to laparoscopy, to perform adnexectomies and hysterectomies without conversion with less pain, fewer postoperative complications and a shorter hospitalization time.

The first evaluations of vNOTES are encouraging and suggest a new era for pelvic surgery: less postoperative pain, fewer complications and facilitation of ambulatory care. Also the videoscopic assistance of the vNOTES is a pedagogical tool for the vaginal route because the field of vision is no longer limited to the operator alone. However, the vNOTES has only been evaluated by the developers of the tool, in monocentric studies and in small numbers. The hysterectomy study evaluated only 35 patients with vNOTES, half of whom had a uterus of less than 280 g. The benefit of vNOTES for uteri smaller than 280 g is not obvious because of the ease of the surgical procedure and the cost of the "classic" vaginal route. Our study would be the first multicentric and academic study on vNOTES to focus specifically on large volume uteri, the most difficult to operate and prone to postoperative complications.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

200

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Bron, Frankrike, 69677
        • Har ikke rekruttert ennå
        • HFME - Hospices Civils de Lyon
        • Hovedetterforsker:
          • Géry LAMBLIN
        • Ta kontakt med:
      • Clermont-Ferrand, Frankrike, 63003
        • Rekruttering
        • CHU Clermont-Ferrand
        • Underetterforsker:
          • Sandra CURINIER, PH
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sandrine CAMPAGNE-LOISEAU, PH
      • Issoire, Frankrike, 63500
        • Har ikke rekruttert ennå
        • Ch Issoire
        • Ta kontakt med:
        • Hovedetterforsker:
          • Aslam MANSOOR, PH
      • Limoges, Frankrike, 87042
        • Har ikke rekruttert ennå
        • CHU LIMOGES - Hôpital de la mère et de l'Enfant
        • Ta kontakt med:
      • Saint-Etienne, Frankrike, 42100
        • Har ikke rekruttert ennå
        • Clinique Mutualiste de Saint-Etienne
        • Ta kontakt med:
        • Hovedetterforsker:
          • Quentin REBOUL, MD
      • Saint-Etienne, Frankrike, 42055
        • Har ikke rekruttert ennå
        • CHU Saint-Etienne
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thomas CORSINI
        • Underetterforsker:
          • Céline CHAULEUR
        • Underetterforsker:
          • Ahamd MEDHI

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Any woman received in preoperative consultation in the Gynecology-Obstetrics Department for a benign pathology of a uterus estimated to be large requiring a hysterectomy.
  • Patient affiliated or entitled to a social security system
  • Patients over 18 years of age
  • Patients having given their agreement to participate and after signing the consent form

Exclusion Criteria:

  • Woman refusing to participate in the study (lack of consent)
  • Non-French speaking woman (unable to conduct a good quality interview of the pregnant woman)
  • Participation in another interventional study.
  • Patient subject to a legal protection measure or unable to express her consent

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: laparoscopic hysterectomy

Laparoscopic Hysterectomy will be performed in a standardized manner with or without surgical robot

laparoscopic hysterectomy uses a standardized procedure with or without surgical robot

Eksperimentell: natural vaginal orifice transluminal endoscopic system for hysterectomies (vNOTES)

Vaginal hysterectomy will be performed in a standardized manner using transluminal endoscopic system

hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of patient with complications
Tidsramme: From surgery to 6 weeks of surgery

The proportion of patients with at least one pre- and post-operative complication at 6 weeks will be estimated along with its 95% confidence interval in each surgical strategy group.

The primary endpoint is a composite endpoint including the occurrence of intraoperative and postoperative complications within 6 weeks of surgery.

Postoperative complications were Infectious complications, Bleeding complications and All hospital readmissions related to the procedure Postoperative complications will be classified according to the Clavien-Dindo classification

Intraoperative complications will be defined as :

  • wounds of nearby organs (bladder, ureters, rectum, colon, small intestine)
  • and bleeding defined as bleeding requiring immediate resumption, intraoperative transfusion and/or decreasing the patient's hemoglobin by more than 2 points compared to the last known preoperative blood sample
From surgery to 6 weeks of surgery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Conversion
Tidsramme: During surgery

Number of patients with conversion during surgery

During surgery

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Post-operative pain
Tidsramme: From surgery to 3 hours of surgery

Maximal Pain measured by a numerical scale : 0 no pain / 10 maximum pain

From surgery to 3 hours of surgery
Short-term postoperative pain
Tidsramme: From surgery to 1 week after surgery

Maximal short-term postoperative pain the first week after surgery measured by a numerical scale (0 no pain / 10 maximum pain) by a daily telephone call

From surgery to 1 week after surgery
Duration of postoperative reflex ileus
Tidsramme: Day 0

Duration of post-operative reflex ileus between the day of the operation and the resumption of a transit (appearance of the first gas) in hours

Day 0
Duration of the operation
Tidsramme: Surgery

operative time will be evaluated between the incision and the end of the closure, in minutes.

Surgery
Duration of hospitalization and the possibility of returning home
Tidsramme: last day of hospitalization

The length of hospital stay will be assessed in days and the possibility of return home by the time in hours from surgical incision to a Chung≥ score of 9/10. The Chung score assesses the possibility of a return home in ambulatory surgery.

last day of hospitalization
Sexual dysfunction
Tidsramme: 3 months

Sexual disorders: sexual life will be assessed by the difference in the specific validated score (self-questionnaire) (PISQ12 with a score ranging from 0 to 48) between the inclusion date and 3 months after surgery for sexually active women.

3 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Céline CHAULEUR, PhD, Centre Hospitalier Universitaire de Saint Etienne

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. desember 2024

Primær fullføring (Antatt)

1. oktober 2026

Studiet fullført (Antatt)

1. desember 2026

Datoer for studieregistrering

Først innsendt

4. mai 2023

Først innsendt som oppfylte QC-kriteriene

22. mai 2023

Først lagt ut (Faktiske)

1. juni 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 21PH265
  • 2023-A01013-42 (Annen identifikator: ANSM)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere